HC Wainwright Has Positive Outlook of uniQure Q1 Earnings

uniQure N.V. (NASDAQ:QURE) – Stock analysts at HC Wainwright lifted their Q1 2026 earnings estimates for shares of uniQure in a research note issued to investors on Tuesday, November 4th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($0.53) per share for the quarter, up from their previous estimate of ($0.59). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure’s Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($2.29) EPS, FY2027 earnings at ($2.68) EPS, FY2028 earnings at ($1.51) EPS and FY2029 earnings at $3.90 EPS.

Several other research analysts have also recently issued reports on QURE. UBS Group set a $95.00 price target on shares of uniQure in a report on Thursday, September 25th. Leerink Partners increased their target price on uniQure from $48.00 to $68.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 24th. Benchmark reissued a “buy” rating on shares of uniQure in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, October 8th. Finally, Guggenheim increased their price objective on uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.75.

uniQure Stock Up 1.0%

Shares of NASDAQ:QURE opened at $27.79 on Thursday. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -7.09 and a beta of 0.59. The firm’s 50-day simple moving average is $42.07 and its 200-day simple moving average is $24.16. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure has a fifty-two week low of $5.50 and a fifty-two week high of $71.50.

Hedge Funds Weigh In On uniQure

Hedge funds have recently added to or reduced their stakes in the business. Private Trust Co. NA purchased a new stake in shares of uniQure in the third quarter valued at about $28,000. Jones Financial Companies Lllp increased its stake in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the last quarter. Mraz Amerine & Associates Inc. purchased a new stake in uniQure in the 1st quarter valued at approximately $106,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in uniQure in the 2nd quarter valued at approximately $117,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other uniQure news, CFO Christian Klemt sold 15,000 shares of the business’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares in the company, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of the company’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the sale, the chief executive officer directly owned 651,454 shares in the company, valued at $27,009,282.84. This trade represents a 25.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 283,126 shares of company stock valued at $11,505,677. 4.79% of the stock is owned by insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.